Result of MEDICA 2022 and Meeting with Consulting company L and Spanish Company

The results of the MEDICA exhibition, UL company introduction, consulting L company in the U.S., and Spanish exclusive rights consultation results

We participated in the MEDICA exhibition in Düsseldorf, Germany, from November 14 to 17, 2022.

We decided to make a consulting contract with L company introduced by UL and distributor sourcing in the U.S. and other regions.

We negotiated with Spain Buyer in Barcelona, Spain on an exclusive supply contract with Colombia.

The following is the result of consultation with buyers from each country who visited Booth during the MEDICA exhibition.

Introduced by UL, which pursues the world's best consulting composed of the world's best experts in each field, Company L was introduced as a close relationship with UL group.

1. Anyfusion cylinder pump

Safety and effectiveness are essential for medicines and medical devices for the recovery of patients' lives and health. In particular, medicines and medical devices are important for critical patients, premature babies, low-weight babies, newborns, and cancer patients, for accurate and precise safety and effectiveness.

As the FDA leader reviewer who reviewed STeP noted, real-time accurate and precise injection of very small amounts of nutrients and drugs according to weight and health conditions is a medical practice that has an important impact on the patient's life. The same goes for critically ill, cancer patients.

Because the existing pumps have not been able to perform these performances properly since they were released, the FDA has set up the injection devices team to manage the matters within the FDA and encouraged the development of alternative technologies.

And in many countries, except the United States, many of medical team don't even know that clinical trials are in a life-threatening situation because of the inaccurate performance of these existing pumps, and there are unfortunate medical accidents that end many patients. 28 million premature babies and underweight babies are born every year.

Anyfusion cylinder pump is the world's first medical device that has significantly improved safety and effectiveness, and can be used quickly by patients and medical staff. The world's top certification agency, the FDA, also directly examines and approves the system for 60 days, the shortest date, including Saturdays and Sundays, and Anyfusion cylinder pump was selected none stop.

I wonder if the winners of the Nobel Prize in medicine have achieved better than this.

Although Anyfusion's source technology has completely overcome safety and effectiveness, these core technologies have become a prerequisite, but due to the limitations of the source technology, existing pumps are a serious problem in safety and effectiveness.

All examiners of the FDA Injection Devices Team and UL (Emergo) consultant were forced to be the best pump experts, and the FDA examiner who recognized Anyfusion's technology recommended STeP, and UL consultant, who fully understood Anyfusion's core technology, was selected as one stop for FDA STeP.

As the FDA has supported the clinical effects of Anyfusion, Anyfusion is a revolutionary innovative medical device that should be used quickly by hospitals in the U.S. market as well as around the world.

UL, which saw through Anyfusion's competitiveness through FDA STeP, readily introduced a company that sources competent US distributors and consults contracts. Company L introduced by UL can predict the capabilities of UL, and we have a lot of hope and expectations for DB and sourcing capabilities.

There are effects and results that cannot be compared with any exhibition.

2. Anyfusion ACPi system

Pharmacists inhale vaporized oil vapor leaked during preparation due to its toxicity, and pharmacists have no choice but to prepare drugs that are vulnerable to contamination on clean benches in aseptic rooms in order to prevent deterioration.

To prevent toxic leaks and contamination risks, pharmacists are wearing uncomfortable clothes.

Until now, only a small portion of Robot preparation for anticancer (injection) preparations, which require high-cost aseptic facilities, have been used, but people (pharmacists) around the world(100%), including all developed countries, are manually prepared with syringes due to low cost-effectiveness and inefficiency.

When we explained the technology to the Ministry of Food and Drug Safety in October, the Ministry of Food and Drug Safety admitted that it was inevitable to adopt it as a force majeure in countries around the world due to high cost-effectiveness and efficiency such as preparation volume and range.

We are looking forward that Company L introduced by UL will introduce a partner who can quickly market and globalize Anyfusion cylinder pump with the world's only perfect safety and competitive effectiveness and Anyfusion ACP System, a digital general-purpose anti-cancer (injection) preparation device for anticancer (injection) preparations that are still highly toxic and contaminated by the manual analog method in the smart era.

We focused on promoting Anyfusion at this MEDICA exhibition and attended to find partners in advanced economies such as the United States, Japan, and Germany, which are 85% of the global market, and we had good results as expected.

In addition to advanced countries, several countries have also been promoting exclusive supply negotiations. There was a request for exclusive rights of S company, which is located in Washington, USA, and has 1.2 billion dollars in annual sales (currently 1.6 trillion won) with patient monitoring system, one of the three core equipment of the intensive care unit, and Germany's existing buyer requested negotiations.

I can realize that buyers from all over the world are lining up to get exclusive rights to our Anyfusion products. The Spanish buyer offered a premium room at the finest hotel in Barcelona. They asked us for exclusive rights to Spain and Portugal, and their US partner said they would play a role and invest in the US in the same way as UL.

Thank you.